Ansell (ANN) H2 2024 earnings summary

Executive summary

• Adjusted EPS was just under $1.06 (US105.5¢), near the upper end of guidance, with statutory EPS at US59.4¢ due to one-off costs.

• Industrial segment delivered record EBIT and margin, offsetting healthcare segment weakness from destocking.

• Strong operating cash flow of $168M, with cash conversion at 131% and significant inventory reduction.

• KCPPE (KBU) acquisition completed July 1, enhancing exposure to high-growth scientific verticals and expected to deliver $10m in synergies by year 3.

• Sustainability initiatives advanced, including reduced emissions, zero waste to landfill, and top-tier ratings from EcoVadis and Sustainalytics.

Financial highlights

• FY24 sales declined 2.2% to $1,619.3m (constant currency -2.9%), with industrial growth offset by lower healthcare sales.

• Industrial segment sales grew 3.3% year-over-year, with margin at an all-time high of 16.5%.

• Healthcare segment sales declined 8% year-over-year, but EBIT margin improved to 12.4% in H2 as destocking eased.

• Foreign exchange provided a $12M sales tailwind but an $8M EBIT headwind due to hedge book losses.

• Excluding $66M in significant items (APIP and acquisition costs), earnings declined 1.3% in constant currency.

Outlook and guidance

• FY25 Adjusted EPS guidance set at $1.07–$1.27, maintaining a wide range due to KBU integration and geopolitical risks.

• Organic constant currency sales growth anticipated in both Industrial and Healthcare; KBU expected to be modestly accretive to EPS in FY25, with synergies realized from FY26.

• EBIT improvement expected from sales growth, productivity gains, and KBU contribution; incremental APIP savings of $17m targeted.

• Raw material and freight costs expected to rise moderately, with price increases to offset in H2.

• Capex planned at $60–70m, including completion of India Surgical facility.